Novel CD20 monoclonal antibodies for lymphoma therapy
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479003/ |